openPR Logo
Press release

Neuroblastoma Treatment Market: Emerging Trends and New Technologies Research 2015 - 2024

04-19-2017 07:23 AM CET | Health & Medicine

Press release from: Transparency Market Research

Neuroblastoma Treatment Market: Emerging Trends and New

Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants below 5 years of age, with peak age group of 2 to 3 years.

According to America Cancer Society, neuroblastoma accounts for over 7% of the total cancer cases in age group of 0 to 14 years of age. Statistics also suggest that the cancer equally affects both sexes across the globe. The cancer is rare and American Society of Cancer estimates over 700 cases in 2014 in the U.S. In more than 90% of the cases neuroblastoma is diagnosed before the age of 5. In rare cases, the cancer can be detected in ultrasound before birth. It also found that some forms of neuroblastoma get cured on their own, while others may require multiple treatments.

Obtain Report Details @ http://www.transparencymarketresearch.com/neuroblastoma-treatment-market.html

Common symptoms of abdominal neuroblastoma include abdominal pain, swelling in legs and altered bowel habits. Neuroblastoma in chest causes symptoms such as wheezing, chest pain, drooping eyelids, and unequal pupils. In majority if the cases, the cancer have already metastasized until it has diagnosed. Most common metastatic sites include bone marrow, skin, liver and bones. Less common symptoms include fever, shortness of breath, high blood pressure, watery diarrhea and uncontrolled eye movement.

Scientists suggest that neuroblastoma causes as a result of genetic mutations; however the exact cause of the genetic mutation leading to neuroblastoma is not clear. Further, only about 2% patients have a history of neuroblastoma, and siblings having history of neuroblastoma imply 10 times more chances of being diagnosed with neuroblastoma. Five year survival rate is the percentage of patients living at least 5 years after diagnosis of the cancer. In intermediate risk patients the 5 year survival rate is over 90%, however in high risk patient the rate is 40% to 50%.

The cancer is diagnosed based on evidence of elevated level of urinary catecholamines and ultrasound or magnetic resonance imaging (MRI) scans. Biopsies are performed to confirm the diagnosis. Localized forms of neuroblastoma are generally treated by surgical removal of tumor.

For more information on this report, fill the form @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8218

Various therapeutics have been adopted to treat metastatic neuroblastoma, these include chemotherapy, immunotherapy, and targeted drug therapy. Drugs such as topotecan, irinotecan, and temozolomide, are being studied for application in neuroblastoma. It has also been found that isotretinoin reduces the risk of reoccurrence of the cancer after treatment. Xalkori (crizotinib) by Pfizer has shown promising results in treating neuroblastoma in infants. The drug targets mutations of the ALK gene which lead to development of neuroblastoma.

Other drugs approved for treatment of neuroblastoma include Adriamycin PFS (Doxorubicin Hydrochloride), Clafen (Cyclophosphamide), Vincasar PFS (Vincristine Sulfate). Various biopharmaceutical companies and research institutes are conducting research for discovery of better treatment options. A research article published in Journal of Clinical Oncology suggests that black and native American neuroblastoma patients have a higher prevalence of high risk disease. Considering restricted prevalence the global market for neuroblastoma is expected to remain small.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neuroblastoma Treatment Market: Emerging Trends and New Technologies Research 2015 - 2024 here

News-ID: 505727 • Views: 213

More Releases from Transparency Market Research

Effervescent Packaging Market: Rising Demand for Fast Dissolving Drug Delivery S …
A recent study by Transparency Market Research (TMR) has detected that the global effervescent packaging market is heavily dependent on product innovation and in the near future, a number of strategic mergers and acquisitions will follow that will define the leader. Some of the key companies currently operating in the global effervescent packaging market are Sanner GmbH, Oracle Packaging, Inc., Unither Pharmaceuticals, Romaco Pharmatechnik GmbH, Parekhplast India Ltd., Tower Laboratories
Form-fill-seal Machines Market: Prosperity of Packaged Food and Beverage Industr …
An up-to-date study by Transparency Market Research (TMR) reveals that the global form-fill-seal machines market is fragmented in nature, although Robert Bosch GmbH does hold a position of strength, accounting for 11% of the overall market shares in 2017. Some of the other key players identified by the report who are making a mark in the global form-fill-seal machines market are: Tokyo Automatic Machinery Works Ltd., Uflex Ltd., Hayssen Flexible
Chatbot Market: Key Players and Production Information analysis
A 27.8% CAGR (Compound Annual Growth Rate) is set to mark the forecast period between 2016 and 2024, as per a Transparency Market Research (TMR) report. And, as per the analysts at TMR , some of the factors that the growth shall be attributed to are increasing popularity and adoption of Artificial Intelligence (AI) across industry verticals, including end-users, and innovation marking the landscape in a big way. This will
Digital Voice Recorder Market: Rising Allocations OnanalysisAnd Innovation
With the presence of a copious number of companies, the global market for digital voice recorder is fragmented with intense competition. In this scenario, top companies are aggressively engaged in technological advancements to serve ever-changing consumer demand, for which they are investing heavily in this market. In the years ahead, these players are likely to concentrate on regional expansion, for which they might resort to business alliances with regional players. Key

All 5 Releases


More Releases for Neuroblastoma

Neuroblastoma Drugs Market Size, Share, Development by 2024
New report published by Global Info Research which offers insights on the Global Neuroblastoma Drugs market. Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under
Neuroblastoma - Pipeline Insight and Review, H1 2018
Market Research HUB has added a new report titled "Neuroblastoma - Pipeline Review, H1 2018, which provides an overview of the Neuroblastoma (Oncology) pipeline landscape. Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include
Neuroblastoma Treatment Pipeline Review H2 2017
Pune, India, 27th November 2017: WiseGuyReports announced addition of new report, titled “Neuroblastoma - Pipeline Review, H2 2017”. Summary Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen
Neuroblastoma - Pipeline Insight and Therapeutic Assessment Reviewed in 2017
A fresh report has been added to the wide database of Market Research Hub (MRH). The research study is titled “Neuroblastoma - Pipeline Review, H2 2017”which encloses important data about the production, consumption, revenue and market share, merged with information related to the market scope and product overview. The report anticipates that the sector for pharmaceutical industry would rise at a positive CAGR during the period 2017-2022. Click here for Free
Neuroblastoma Treatment Market to Register Substantial Expansion by 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants
04-14-2017 | Health & Medicine
TMR
Global Neuroblastoma Treatment Market: Latest Trends and Insights 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants